Characterization of Predictors of Response or Resistance to ICIs in NSCLC
PD-L1 expression density and cytotoxic T cells were identified as potential biomarkers for outcomes with ICIs in patients with NSCLC.
Diagnosis & Disease Information
Apatinib Plus Gefitinib Improved PFS in EGFR-Mutated NSCLC
The addition of apatinib to gefitinib prolonged PFS compared with gefitinib among treatment-naive patients with EGFR-mutated NSCLC.
No Benefit, Higher Toxicities With Postoperative Conformal RT in Stage IIIAN2 NSCLC
The use of modern postoperative conformal radiotherapy did not improve DFS and was associated with toxicities among patients with stage IIIAN2 NSCLC.
Longitudinal NGS May Identify Patients At Risk for Hyperprogression or Death From ICIs
NGS of longitudinal samples from patients with advanced NSCLC receiving ICIs identified changes associated with hyperprogression and early death.
KRAS Inhibitor Shows Favorable Activity in Advanced NSCLC
Results from a phase 1 trial suggest a KRASG12C inhibitor has a favorable safety profile and antitumor activity in advanced NSCLC.
Characteristics and Treatment Patterns of KRASG12C-Mutated NSCLC
An analysis of from the Flatiron Health Network found that some patients with NSCLC with a KRASG12C mutation do not receive systemic therapy.
- Loading...
Loading...
Next post in ESMO Virtual Congress 2020 Lung Cancer In-depth
Loading... 
Loading...